Guggenheim Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by Guggenheim from $45.00 to $52.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target suggests a potential upside of 12.99% from the stock’s previous close.

A number of other brokerages have also recently commented on KYMR. Truist Financial reiterated a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. B. Riley upped their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. Morgan Stanley lifted their target price on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 14th. Finally, Leerink Partners restated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Monday, September 9th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.15.

Kymera Therapeutics Trading Down 0.3 %

Kymera Therapeutics stock traded down $0.15 during midday trading on Friday, reaching $46.02. The company’s stock had a trading volume of 247,846 shares, compared to its average volume of 596,527. The stock has a market cap of $2.84 billion, a PE ratio of -19.02 and a beta of 2.21. Kymera Therapeutics has a 52 week low of $9.60 and a 52 week high of $53.27. The business has a 50-day moving average price of $47.06 and a 200-day moving average price of $40.57.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The firm’s quarterly revenue was down 20.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.90) EPS. As a group, research analysts predict that Kymera Therapeutics will post -2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Harbor Capital Advisors Inc. increased its stake in Kymera Therapeutics by 30.0% in the third quarter. Harbor Capital Advisors Inc. now owns 40,303 shares of the company’s stock valued at $1,908,000 after purchasing an additional 9,292 shares in the last quarter. Integrated Advisors Network LLC bought a new stake in Kymera Therapeutics in the 3rd quarter valued at about $294,000. China Universal Asset Management Co. Ltd. raised its stake in Kymera Therapeutics by 72.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,422 shares of the company’s stock worth $588,000 after buying an additional 5,214 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after acquiring an additional 504 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in Kymera Therapeutics in the third quarter valued at approximately $61,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.